NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

National Research Council (US) Committee on Intellectual Property Rights in Genomic and Protein Research and Innovation; Merrill SA, Mazza AM, editors. Reaping the Benefits of Genomic and Proteomic Research: Intellectual Property Rights, Innovation, and Public Health. Washington (DC): National Academies Press (US); 2006.

Cover of Reaping the Benefits of Genomic and Proteomic Research

Reaping the Benefits of Genomic and Proteomic Research: Intellectual Property Rights, Innovation, and Public Health.

Show details

References

  1. Abate T. Biotech firms rushing to patent gene fragments. The San Francisco Chronicle. 1999 October 18:B14.
  2. Alberts B, Klug Sir A. The human genome itself must be freely available to all humankind. Nature. 2000;404(6776):325. [PubMed: 10746695]
  3. Atkinson RC, Beachy RN, Conway G, Cordova FA, Fox MA, Holbrook KA, Klessig DF, McCormick RL, McPherson PM, Rawlings HR III, Rapson R, Vanderhoef LN, Wiley JD, Young CE. Public sector collaboration for agricultural IP management. Science. 2003;301(5630):174–175. [PubMed: 12855794]
  4. Avery OT, MacLeod CM, McCarty M. Studies on the chemical nature of the substance inducing transformation of Pneumococcal types: induction of transformation by a Deoxyribonucleic Acid fraction isolated from Pneumococus Type III. J. Exp. Med. 1944;79(2):137–157. [PMC free article: PMC2135445] [PubMed: 19871359]
  5. Berg JM. Presentation to Committee on Intellectual Property in Genomic and Protein Research and Innovation at February 11-12 meeting.2004.
  6. Blumenthal D, Campbell EG, Anderson MS, Causino N, Louis KS. Withholding research results in academic life science: evidence from a national survey of faculty. JAMA. 1997;277(15):1224–1228. [PubMed: 9103347]
  7. Blumenthal D, Campbell EG, Causino N, Louis KS. Participation of life-science faculty in research relationships with industry. N. Engl. J. Med. 1996;335(23):1734–1739. [PubMed: 8929266]
  8. Blumenthal D, Gluck M, Louis KS, Stoto MA, Wise D. University-industry research relationships in biotechnology: implications for the university. Science. 1986;232(4756):1361–1366. [PubMed: 3715452]
  9. Bodenheimer T. Uneasy alliance: clinical investigators and the pharmaceutical industry. N. Engl. J. Med. 2000;342(20):1539–1544. [PubMed: 10816196]
  10. Bratic VW, Webster S, Matthews S, Harrell RS. How patent pools can avoid competition concerns. Managing Intellectual Property. 2005;148:44–47.
  11. Bresalier RS, Sandler RS, Quan H, Bolognese JA, Oxenius B, Horgan K, Lines C, Riddell R, Morton D, Lanas A, Konstam MA, Baron JA. Adenomatous Polyp Prevention on Vioxx (APPROVe) Trial Investigators. Cardiovascular events associated with Rofecoxib in a colorectal adenoma chemoprevention trial. N. Engl. J. Med. 2005;352(11):1092–1102. [PubMed: 15713943]
  12. Campbell EG, Clarridge BR, Gokhale M, Birenbaum L, Hilgartner S, Holtzman NA, Blumenthal D. Data withholding in academic genetics: evidence from a national survey. JAMA. 2002;287(15):473–480. [PubMed: 11798369]
  13. Carr S, Aebersold R, Baldwin M, Burlingame A, Clauser K, Nesvizhskii A. The need for guidelines in publication of peptide and protein identification data: Working Group on Publication Guidelines for Peptide and Protein Identification Data. Mol. Cell. Proteomics. 2004;3:531–533. [PubMed: 15075378]
  14. Cho MK, Illangasekare S, Weaver MA, Leonard DG, Merz JF. Effects of patents and licenses on the provision of clinical genetic testing services. J. Mol. Diagn. 2003;5(1):3–8. [PMC free article: PMC1907368] [PubMed: 12552073]
  15. Clark J, Piccolo J, Stanton B, Tyson K. Patent Pools: A Solution to the Problem of Access in Biotechnology Patents. 2000. Available atwww.uspto.gov/web/offices/pac/dapp/opla/patentpool.pdf.
  16. Collins FS. Positional cloning moves from perditional to traditional. Nat. Genet. 1995;9(4):347–350. [PubMed: 7795639]
  17. Collins F. Intellectual property and genomics: a rocky relationship: remarks to Committee on Intellectual Property in Genomic and Protein Research and Innovation at February 11-12 meeting.2004.
  18. Crick F. Of Molecules and Men. Seattle: University of Washington Press; 1967.
  19. Dickson D. UK clinical geneticists ask for ban on the patenting of human genes. Nature. 1993;366(6454):391. [PubMed: 8247135]
  20. Dueker KS. Biobusiness on campus: commercialization of university-developed biomedical technologies. Food Drug Law J. 1997;52(4):453–509. [PubMed: 10346675]
  21. Dulbecco R. An Essay on Evolutionary Epistemology. Palo Alto: Blackwell Scientific Publications; 1986. Mind from Matter?
  22. Easton DF, Bishop DT, Ford D, Crockford GP. Genetic linkage analysis in familial breast and ovarian cancer: results from 214 families. The Breast Cancer Linkage Consortium. Am. J. Hum. Genet. 1993;52(4):678–701. [PMC free article: PMC1682082] [PubMed: 8460634]
  23. Eisenberg RS. Patenting the human genome. Emory Law J. 1990;39(3):721–745. [PubMed: 11653907]
  24. Eisenberg R. Intellectual property at the public-private divide: the case of large-scale cDNA sequencing. Univ. Chi. Law. School Roundtable. 1996;3:557–573.
  25. Eisenberg RS. Intellectual Property Rights and Research Tools in Molecular Biology: Summary of a Workshop Held at the National Academy of Sciences. Washington, D.C: National Academy Press; 1997. Patenting research tools and the law.
  26. Eisenberg RS. Bargaining over the transfer of proprietary research tools. In: Dreyfuss R, Zimmerman DL, First H, editors. Expanding the Boundaries of Intellectual Property. Oxford: Oxford University Press; 2001. pp. 223–249.
  27. Federal Trade Commission. To promote innovation: The proper balance of competition and patent law and policy. Washington, D.C: Federal Trade Commission; 2003.
  28. Finnegan Henderson, Farabow Garrett, Dunner LLP. Biotechnology Innovation Report 2004: Benchmarks. 2004 June
  29. Firlik AD, Lowry DW. Is academic medicine for sale? N. Engl. J. Med. 2000;343(7):509–510. [PubMed: 10950674]
  30. Gluck M, Blumenthal D, Stoto M. University-industry research relationships in the life sciences: Implications for students and post-doctoral fellows. Research Policy. 1987;16:327–336.
  31. Graveley BR. Mutually exclusive splicing of the insect Dscam pre-mRNA directed by competing intronic RNA secondary structures. Cell. 2005;123(1):65–73. [PMC free article: PMC2366815] [PubMed: 16213213]
  32. Gusella JF, Wexler NS, Conneally PM, Naylor SL, Anderson MA, Tanzi RE, Watkins PC, Ottina K, Wallace MR, Sakaguchi AY, Young AB, Shoulson I, Bonilla E, Martin JB. A polymorphic DNA marker genetically linked to Huntington's disease. Nature. 1983;306(5940):234–238. [PubMed: 6316146]
  33. Hall JM, Lee MK, Newman B, Morrow JE, Anderson LA, Huey B, King MC. Linkage of early-onset familial breast cancer to chromosome 17q21. Science. 1990;250 (4988):1684–1689. [PubMed: 2270482]
  34. Heller MA, Eisenberg RS. Can patents deter innovation? The anticommons in biomedical research. Science. 1998;280(5364):698–701. [PubMed: 9563938]
  35. Henry MR, Cho MK, Weaver MA, Merz JF. DNA patenting and licensing. Science. 2002;297(5585):1279. [PMC free article: PMC2220017] [PubMed: 12193770]
  36. Hollen T. NIH researchers receive cut-price BRCA test. Nat. Med. 2000;6(6):610. [PubMed: 10835655]
  37. Howlett M, Christie AF. An analysis of the approach of the European, Japanese, and United States patent offices to patenting partial DNA sequences (ESTs) University of Melbourne Faculty of Law, Legal Studies Research Paper No. 82; 2004. Available atssrn.com/abstract=573184.
  38. Hughes SS. Making dollars out of DNA. The first major patent in biotechnology and the commercialization of molecular biology, 1974-1980. Isis. 2001;92(3):541–75. [PubMed: 11810894]
  39. Jensen K, Murray F. IP Landscape of the Human Genome. Science. 2005;310:239–240. [PubMed: 16224006]
  40. Johnson RP, Kaur A. HIV: viral blitzkrieg. Nature. 2005;434(7037):1080–1081. [PubMed: 15858559]
  41. Kastan MB, Bartek J. Cell-cycle checkpoints and cancer. Nature. 2004;432(7015):316–323. [PubMed: 15549093]
  42. Kaufman RJ. Genetic engineering of factor VIII. Nature. 1989;342(6246):207–208. [PubMed: 2509944]
  43. Kaul R, Gao GP, Balamurugan K, Matalon R. Cloning of the human aspartoacylase cDNA and a common missense mutation in Canavan disease. Nat. Genet. 1993;5(2):118–123. [PubMed: 8252036]
  44. Kendrew JC, Bodo G, Dintzis HM, Parrish RG, Wyckoff H, Phillips DC. A three-dimensional model of the myoglobin molecule obtained by x-ray analysis. Nature. 1958;181(4610):662–666. [PubMed: 13517261]
  45. Kenney M. Biotechnology: The University-Industry Complex. New Haven: Yale University Press; 1986.
  46. Kilpatrick MM, Lowry DW, Firlik AD, Yonas H, Marion DW. Hyperthermia in the neurosurgical intensive care unit. Neurosurgery. 2000;47(4):850–856. [PubMed: 11014424]
  47. Kodish E, Murray T, Whitehouse P. Conflict of interest in university-industry research relationships: realities, politics, and values. Acad. Med. 1996;71(12):1287–1290. [PubMed: 9114885]
  48. Kristiansen OP, Larsen ZM, Pociot F. CTLA-4 in autoimmune diseases–a general susceptibility gene to autoimmunity? Genes Immun. 2000;1(3):170–84. [PubMed: 11196709]
  49. Lander ES, Linton LM, Birren B, Nusbaum C, Zody MC, et al. Initial sequencing and analysis of the human genome. Nature. 2001;409(6822):860–921. [PubMed: 11237011]
  50. Lawrence S. U.S. biopatents decline. Nat. Nat. Biotechnol. 2004;22(7):797.
  51. MacDonald ME, Ambrose CM, Duyao MP, Myers RH, Lin C, et al. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. The Huntington's Disease Collaborative Research Group. Cell. 1993;72(6):971–983. [PubMed: 8458085]
  52. Merz JF. Disease gene patents: Overcoming unethical constraints on clinical laboratory medicine. Clin. Chem. 1999;45(3):324–330. [PubMed: 10053032]
  53. Merz JF, Cho MK. Disease genes are not patentable: a rebuttal to McGee. Camb. Q. Healthc. Ethics. 1998;7:425–428. [PubMed: 9752584]
  54. Merz JF, Leonard DG, Kriss AG, Cho MK. Industry opposes genomic legislation. Nat. Biotechnol. 2002;20(7):657. [PubMed: 12089543]
  55. Michelsohn AM. Biotechnology Innovation Report 2004: Benchmarks. Washington, D.C: Finnegan, Henderson, Farabow, Garrett & Dunner, LLP; 2004.
  56. Milstein C. Patents on scientific discoveries are unfair and potentially dangerous. The Scientist. 1993;7(21):11.
  57. Mowery David, Nelson Frichard, Sampat Bhaven, Ziedonis Arvids. Ivory Tower and Industrial Innovation: University-Industry Technology Transfer Before and After the Bayh-Dole Act. Stanford University Press; 2004.
  58. Murray F, Stern S. Do Formal Intellectual Property Rights Hinder the Free Flow of Scientific Knowledge? An Empirical Test of the Anti-Commons Hypothesis. 2004 Unpublished manuscript.
  59. National Research Council. Committee on Mapping and Sequencing the Human Genome. Mapping and Sequencing the Human Genome. Washington, D.C: National Academy Press; 1988.
  60. National Research Council. Summary of a Workshop Held at the National Academy of Sciences. Washington, D.C: National Academy Press; February 15-16, 1996, 1997. Intellectual Property Rights and Research Tools in Molecular biology. [PubMed: 25121313]
  61. National Research Council. Committee on Responsibilities of Authorship in the Biological Sciences. Sharing Publication-Related Data and Materials: Responsibilities of Authorship in the Life Sciences. Washington D.C: The National Academies Press; 2003.
  62. Merrill SA, Levin RC, Myers MB, editors. National Research Council. Committee on Intellectual Property Rights in the Knowledge-Based Economy. A Patent System for the 21st Century. Washington, D.C: The National Academies Press; 2004.
  63. National Science Foundation. National Science Board. Science and Engineering Indicators. Washington, D.C: Government Printing Office; 2004.
  64. National Institutes of Health. Report of the National Institutes of Health (NIH) Working Group on Research Tools. 1998. [Accessed June 22, 2005]. Available atwww.nih.gov./news/researchtools/index.htm.
  65. Oosterwegel MA, Greenwald RJ, Mandelbrot DA, Lorsbach RB, Sharpe AH. CTLA-4 and T cell activation. Curr. Opin. Immunol. 1999;11(3):294–300. [PubMed: 10375557]
  66. Organisation for Economic Co-operation and Development. Genetic Inventions, Intellectual Property Rights and Licensing Practices. 2002. [Accessed June 22, 2005]. p. 48. Available atwww.oecd.org/dataoecd/42/21/2491084.pdf.
  67. Organisation for Economic Co-operation and Development. Intellectual Property and Competition Policy in the Biotechnology Industry. 2005. [Accessed June 22, 2005]. Available atwww.oecd.org/dataoecd/36/4/35040373.pdf.
  68. Patent and Trademark Act Amendments of 1980 (Bayh-Dole Act), Pub. L. No. 96-517, 94 Stat. 3015 (codified in scattered sections of 35 U.S.C.)

  69. Petricoin EF, Liotaa LA. Proteomic analysis at the bedside: Early detection of cancer. Trends Biotechnol. 2002;20(12 Suppl):S30–4. [PubMed: 12570157]
  70. Pressman L, Burgess R, Cook-Deegan RM, McCormack SJ, Nami-Wolk I, Soucy M, Walters L. Patenting and licensing practices for DNA-based patents at U.S. academic institutions. Nat. Biotechnol. 2005 In press.
  71. Principles and Guidelines for Recipients of NIH Research Grants and Contracts on Obtaining and Disseminating Biomedical Research Resources: Final Notice, 64. Fed. Reg. 72:090. (proposed Dec. 23, 1999)
  72. Rosenshine I, Umanski T, Ilan O, Peleg-Lavi A, Fang Y, Nisan I, Friedberg D. Regulation of Virulence Genes and Host Specificity by EPEC. Presented at UNESCO Workshop on Science for Peace and Regional Scientific Cooperation in Molecular Biology, Microbiology, and Biotechnology; Jerusalem, Israel. 1999.
  73. Sampat B. Patents on Academic Genomic Discoveries: Effects on Biomedical Research. Working Paper, Department of Health Management and Policy; University of Michigan; Forthcoming.
  74. Sanger F, Nicklen S, Coulson AR. DNA sequencing with chain-terminating inhibitors. Proc. Natl. Acad. Sci. 1977;74(12):5463–5647. [PMC free article: PMC431765] [PubMed: 271968]
  75. Service RF. Proteomics: Gene and protein patents get ready to go head to head. Science. 2001;294(5549):2082–2083. [PubMed: 11739934]
  76. Sheridan C. Curie's victory over BRCA1. Nat. Biotechnol. 2004;22(7):797.
  77. Shimbo I, Nakajima R, Yokohama S, Sumikura K. Patent protection for protein structure analysis. Nat. Biotechnol. 2004;22(1):109–112. [PubMed: 14704710]
  78. Staudt LM, Dave S. The biology of human lymphoid malignancies revealed by gene expression profiling. Adv. Immunol. 2005;87:163–208. [PMC free article: PMC1351148] [PubMed: 16102574]
  79. Thackray A, editor. Private Science: Biotechnology and the Rise of the Molecular Sciences. Philadelphia: University of Pennsylvania Press; 1998.
  80. Thursby MC, Thursby J, Dechenaux E. Shirking Sharing Risk, and Shelving: The role of University License Contracts. Cambridge, MA: National Bureau of Economic Research; 2005. (Working Paper No. 11128)
  81. U.S. Congress, Office of Technology Assessment. Genome Projects: How Big? How Fast? OTA-BA-273. Washington, D.C: U.S. Government Printing Office; 1988. Mapping Our Genes.
  82. Venter JC, Adams MD, Myers EW, Li PW, Mural RJ, et al. The sequence of the human genome. Science. 2001;291(5507):1304–1351. [PubMed: 11181995]
  83. Vermij P. BRAC1 patent revisited. Nat. Biotechnol. 2005;23(3):277.
  84. Vinarov SD. Patent protection for structural genomics-related inventions. J. Struct. Funct. Genomics. 2003;4(2-3):191–209. [PubMed: 14649303]
  85. Walsh JP, Arora A, Cohen WM. Research tool patent and licensing and biomedical innovation. In: Cohen W, Merrill S, editors. Patents in the Knowledge-Based Economy. Washington, D.C: The National Academies Press; 2003. pp. 285–340.
  86. Walsh JP, Cho C, Cohen WM. Patents, Material Transfers, and Access to Research Inputs in Biomedical Research. 2005. athttp://www.uic.edu/~jwalsh/NASreport. html.
  87. Watson JD, Crick FH. Molecular structure of nucleic acids; a structure for deoxyribose nucleic acid. Nature. 1953;171(4356):737–738. [PubMed: 13054692]
  88. Watson FL, Puttmann-Holgado R, Thomas F, Lamar DL, Hughes M, Kondo M, Rebel VI, Schmucker D. Extensive diversity of Ig-superfamily proteins in the immune system of insects. Science. 2005;309(5742):1874–1878. [PubMed: 16109846]
  89. Wright B, Pardey PG. Intellectual property protection: A challenge to agricultural biotechnology innovation developing countries. 2005 Unpublished paper.
  90. Yamamoto Y, Gaynor RB. Role of the NF-kappaB pathway in the pathogenesis of human disease states. Curr. Mol. Med. 2001;1(3):287–296. [PubMed: 11899077]
Copyright © 2006, National Academy of Sciences.
Bookshelf ID: NBK19857

Views

  • PubReader
  • Print View
  • Cite this Page
  • PDF version of this title (1.0M)

Related information

  • PMC
    PubMed Central citations
  • PubMed
    Links to PubMed

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...